• Novartis.com
  • Annual Reporting Suite
  • Investors
  • Coronavirus
  • Global
  • Novartis site directory
Novartis

Reporting Hub 2021

  • Novartis in Society
    Integrated Report 2021
  • Novartis Annual Report
  • US Securities & Exchange Commission Form 20-F
  • Further Disclosures and
    Reporting Archive
  • Novartis in Society
    • Introduction
      • About this report
      • 2021 at a glance
      • Chairman’s letter
      • CEO’s letter
      Introduction Introduction
    • Our approach
      • Who we are
      • Our business environment
      • Our stakeholders
      • Our 2021 materiality assessment
      • Our strategy
        • Our approach
        • Overview
        • ESG management targets
      • How we create value
        • Our approach
        • Our business model
        • Measuring and valuing our impact
      • How we manage risk
        • Our approach
        • Overview
        • Risks in 2021
        • Risks in focus
      Our approach Our approach
    • Our performance
      • Financial performance
        • Our performance
        • Group performance
        • Innovative Medicines
        • Sandoz
        • 2021 news highlights
      • Deliver transformative innovation
        • Our performance
        • Overview
        • Our approach to R&D
        • Advancing a strong and diverse pipeline
        • Advanced technology platforms
        • Innovation for global health
        • Putting patients at the center of our clinical trials
      • Embrace operational excellence
        • Our performance
        • Overview
        • Strengthening product launches
        • Transforming manufacturing
        • Ensuring patient health and safety
        • Managing our supply chain responsibly
        • Delivering effective business services
      • Go big on data and digital
        • Our performance
        • Overview
        • Accelerating innovation 
        • Engaging customers
        • Digital health solutions
        • Embedding data and digital in our operations
      • Unleash the power of our people
        • Our performance
        • Overview
        • Evolving ways of working
        • Learning and development
        • Diversity and inclusion
        • Supporting and protecting our employees
        • Engagement and volunteering
      • Build trust with society
        • Our performance
        • Overview
        • Leading the way on access and global health
          • Access principle 1: research and development
          • Access principle 2: affordability
          • Access principle 3: strengthening healthcare systems
          • Expanding access through generics and biosimilars
        • Holding ourselves to high ethical standards
          • Upholding our commitment to human rights
          • Encouraging employees to speak up
          • Commitment to transparency and disclosure
        • Being a responsible citizen
          • Enhancing environmental sustainability
          • Advancing our program to combat antimicrobial resistance
          • Conducting animal research responsibly
      Our performance Our performance
    • Our corporate governance approach
      • Our corporate governance framework
      • Our Board of Directors
      • Our Executive Committee
      • Ethics, risk and compliance
      • Internal Audit
      • Compensation Report summary
      Our corporate governance approach Our corporate governance approach
    • Appendices
      • Performance indicators 2021
      • GRI Index
      • SASB Index
      • TCFD disclosure
      • Environmental, Social and Governance (ESG) Index
      • External initiatives and membership of associations
      • Selected adaptive development projects
      • Supplier spend 2021
      • Assurance Report
      Appendices Appendices
    • Photo stories
      • Improving heart health through digital technology
      • On the frontline in the fight against malaria
      • A Novartis employee finds her true self
      Photo stories Photo stories
  • Annual Reporting Suite
  • Homepage Welcome
    • Reporting Hub
      Reporting Hub Welcome
    • Downloads
      Downloads Downloads

Search by topic

Topic filter

Results

  • No filter selected.
  • en Novartis in Society
  • Novartis in Society Introduction
  • Introduction About this report
  • Introduction 2021 at a glance
  • Introduction Chairman’s letter
  • Introduction CEO’s letter
  • Novartis in Society Our approach
  • Our approach Who we are
  • Our approach Our business environment
  • Our approach Our stakeholders
  • Our approach Our 2021 materiality assessment
  • Our approach Our strategy
  • Our strategy Overview
  • Our strategy ESG management targets
  • Our approach How we create value
  • How we create value Our business model
  • How we create value Measuring and valuing our impact
  • Our approach How we manage risk
  • How we manage risk Overview
  • How we manage risk Risks in 2021
  • How we manage risk Risks in focus
  • Novartis in Society Our performance
  • Our performance Financial performance
  • Financial performance Group performance
  • Financial performance Innovative Medicines
  • Financial performance Sandoz
  • Financial performance 2021 news highlights
  • Our performance Deliver transformative innovation
  • Deliver transformative innovation Overview
  • Deliver transformative innovation Our approach to R&D
  • Deliver transformative innovation Advancing a strong and diverse pipeline
  • Deliver transformative innovation Advanced technology platforms
  • Deliver transformative innovation Innovation for global health
  • Deliver transformative innovation Putting patients at the center of our clinical trials
  • Our performance Embrace operational excellence
  • Embrace operational excellence Overview
  • Embrace operational excellence Strengthening product launches
  • Embrace operational excellence Transforming manufacturing
  • Embrace operational excellence Ensuring patient health and safety
  • Embrace operational excellence Managing our supply chain responsibly
  • Embrace operational excellence Delivering effective business services
  • Our performance Go big on data and digital
  • Go big on data and digital Overview
  • Go big on data and digital Accelerating innovation 
  • Go big on data and digital Engaging customers
  • Go big on data and digital Digital health solutions
  • Go big on data and digital Embedding data and digital in our operations
  • Our performance Unleash the power of our people
  • Unleash the power of our people Overview
  • Unleash the power of our people Evolving ways of working
  • Unleash the power of our people Learning and development
  • Unleash the power of our people Diversity and inclusion
  • Unleash the power of our people Supporting and protecting our employees
  • Unleash the power of our people Engagement and volunteering
  • Our performance Build trust with society
  • Build trust with society Overview
  • Build trust with society Leading the way on access and global health
  • Leading the way on access and global health Access principle 1: research and development
  • Leading the way on access and global health Access principle 2: affordability
  • Leading the way on access and global health Access principle 3: strengthening healthcare systems
  • Leading the way on access and global health Expanding access through generics and biosimilars
  • Build trust with society Holding ourselves to high ethical standards
  • Holding ourselves to high ethical standards Upholding our commitment to human rights
  • Holding ourselves to high ethical standards Encouraging employees to speak up
  • Holding ourselves to high ethical standards Commitment to transparency and disclosure
  • Build trust with society Being a responsible citizen
  • Being a responsible citizen Enhancing environmental sustainability
  • Being a responsible citizen Advancing our program to combat antimicrobial resistance
  • Being a responsible citizen Conducting animal research responsibly
  • Novartis in Society Our corporate governance approach
  • Our corporate governance approach Our corporate governance framework
  • Our corporate governance approach Our Board of Directors
  • Our corporate governance approach Our Executive Committee
  • Our corporate governance approach Ethics, risk and compliance
  • Our corporate governance approach Internal Audit
  • Our corporate governance approach Compensation Report summary
  • Novartis in Society Appendices
  • Appendices Performance indicators 2021
  • Appendices GRI Index
  • Appendices SASB Index
  • Appendices TCFD disclosure
  • Appendices External initiatives and membership of associations
  • Appendices Selected adaptive development projects
  • Appendices Supplier spend 2021
  • Appendices Assurance Report
  • Novartis in Society Photo stories
  • Photo stories Improving heart health through digital technology
  • Photo stories On the frontline in the fight against malaria
  • Photo stories A Novartis employee finds her true self

Reporting Hub
2021

Novartis in Society
Integrated Report 2021

The Integrated Report explains who we are and what we do, and highlights our progress against the company’s five strategic priorities in 2021.

Regulatory Disclosures

Novartis Annual Report
US Securities & Exchange Commission Form 20-F

Further Disclosures and
Reporting Archive

Read and download the 2021 Annual Report and Form 20-F, and access our reporting archive.

Reporting Hub 2021

Services
  • Key figures comparison
  • Downloads

© 2022 Novartis AG

  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Forward-looking statements
  • Site Map
  • Cookie Settings
  • Accessibility
Novartis Site Directory

This site is intended for a global audience.